Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 52, 3043-3047, June 1, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bruckner, A.
Right arrow Articles by Remold, H. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bruckner, A.
Right arrow Articles by Remold, H. G.

Endogenous Receptor-bound Urokinase Mediates Tissue Invasion of the Human Lung Carcinoma Cell Lines A549 and Calu-11

A. Bruckner, A. E. Filderman, J. C. Kirchheimer, B. R. Binder and H. G. Remold2

Department of Rheumatology and Immunology, Brigham and Women's Hospital [A. B., H. G. R.], Department of Pulmonary Medicine, New England Deaconess Hospital [A. E. F.], and Harvard Medical School [A. B., A. E. F., H. G. R.], Boston, Massachusetts 02115; and Departments of Orthopedics and Physiology, University of Vienna, Vienna, Austria [J. C. K., B. R. B.]

Macrophage colony-stimulating factor (CSF-1) increases the tissue invasive potential of the CSF-1 receptor-bearing lung carcinoma cell lines A549 and Calu-1 by increasing the number of endogenously bound urokinase-type plasminogen activators (u-PA)s on these cells. CSF-1, at concentrations which optimize invasion of A549 and Calu-1 cells into human amnion membranes (250 ng/ml), maximally augments the number of u-PA receptors occupied by endogenously produced urokinase. Preincubation of A549 and Calu-1 cells with the anti-u-PA monoclonal antibody MPW5UK (25 µg/ml) or with a 20- to 40-fold stoichiometric excess of fluid phase type 2 plasminogen activator inhibitor abrogates invasiveness, indicating that functionally active cell surface u-PA is essential for tissue invasion. In contrast, fluid phase type 1 plasminogen activator inhibitor (PAI-1, 5–15 units/ml) does not inhibit invasiveness unless preincubated with the amnion membranes. Inhibition of invasion by PAI-1 is abolished by presaturating the amnion membranes with anti-itronectin monoclonal antibody (10 µg/ml) which prevents binding of PAI-1 to tissue-associated vitronectin. Binding of PAI-1 to tissue vitronectin is therefore a prerequisite for its inhibitory action. Thus, endogenously receptor-bound u-PA is the primary protease mediating CSF-1-induced tissue invasiveness of the lung carcinoma cell lines A549 and Calu-1.

1 Supported by National Institutes of Health Research Grant AI22532 and by a grant from the Oncology Foundation, University of Vienna, Austria.

2 To whom requests for reprints should be addressed, at Department of Rheumatology/Immunology, Brigham and Women's Hospital, Room 513, LMRC, 221 Longwood Ave., Boston, MA 02115.

Received 11/ 1/91. Accepted 3/25/92.




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. Aharinejad, D. Abraham, P. Paulus, H. Abri, M. Hofmann, K. Grossschmidt, R. Schafer, E. R. Stanley, and R. Hofbauer
Colony-stimulating Factor-1 Antisense Treatment Suppresses Growth of Human Tumor Xenografts in Mice
Cancer Res., September 15, 2002; 62(18): 5317 - 5324.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
H. Shiomi, Y. Eguchi, T. Tani, M. Kodama, and T. Hattori
Cellular Distribution and Clinical Value of Urokinase-Type Plasminogen Activator, Its Receptor, and Plasminogen Activator Inhibitor-2 in Esophageal Squamous Cell Carcinoma
Am. J. Pathol., February 1, 2000; 156(2): 567 - 575.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Allgayer, H. Wang, Y. Wang, M. M. Heiss, R. Bauer, O. Nyormoi, and D. Boyd
Transactivation of the Urokinase-type Plasminogen Activator Receptor Gene through a Novel Promoter Motif Bound with an Activator Protein-2alpha -related Factor
J. Biol. Chem., February 19, 1999; 274(8): 4702 - 4714.
[Abstract] [Full Text] [PDF]


Home page
Reproductive SciencesHome page
N. Keshava, S. Gubba, and R. R. Tekmal
Overexpression of Macrophage Colony-Stimulating Factor (CSF-I) and Its Receptor, c-fms, in Normal Ovarian Granulosa Cells Leads to Cell Proliferation and Tumorigenesis
Reproductive Sciences, January 1, 1999; 6(1): 41 - 49.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
Y. Koshelnick, M. Ehart, P. Hufnagl, P. C. Heinrich, and B. R. Binder
Urokinase Receptor Is Associated with the Components of the JAK1/STAT1 Signaling Pathway and Leads to Activation of This Pathway upon Receptor Clustering in the Human Kidney Epithelial Tumor Cell Line TCL-598
J. Biol. Chem., November 7, 1997; 272(45): 28563 - 28567.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1992 by the American Association for Cancer Research.